Typical PA requirements include: Confirmed diagnosis of type 2 diabetes or obesity Documented BMI (often 30 or 27 with comorbidities) Failed trials of other medications Lifestyle modification attempts Recent A1C lab values (for diabetes) Documentation Must Include Height and weight with calculated BMI Diagnosis supporting medical necessity Treatment plan Follow-up and monitoring plan Compliance & Audit Risk GLP-1 medications are a high-risk audit target due to: Rapid growth in utilization High drug cost Off-label prescribing Weight-loss demand Common audit issues: Incorrect diagnosis codes Missing BMI documentation Lack of medical necessity Billing weight-loss drugs to Medicare Inappropriate use of unclassified J-codes Medicare Coverage Rules Medicare Part D generally does not cover weight-loss drugs , even if FDA-approved for obesity
During a public hearing on the legislation this spring, Patricia Wilton, executive council for the Board of Medical Examiners, acknowledged the rule related to obesity is outdated and needs to be changed
For patients with type 2 diabetes, high-glycemic fast food options can cause postprandial glucose spikes that challenge optimal blood sugar control
doi: 10.1097/MD.0000000000032892
GLP-1s are taking up significant fill-finish capacity in the pharmaceutical industry
At En Vogue IV Therapy & Wellness, our healthcare providers use BMI as a key screening tool to identify which patients will benefit most from treatments like tirzepatide
